Tenax Therapeutics (TENX) Total Non-Current Liabilities (2012 - 2022)
Tenax Therapeutics (TENX) reported Total Non-Current Liabilities of $64196.0 for Q4 2022, down 65.03% on a YoY basis from $183589.0 in Q4 2021, and down 32.67% sequentially from $95347.0 in Q3 2022.
Tenax Therapeutics (TENX) Total Non-Current Liabilities (2012 - 2022) Analysis & Trends
Tenax Therapeutics (TENX) has 10 years of Total Non-Current Liabilities data on file, last reported at $64196.0 in Q4 2022.
- For the quarter ending Q4 2022, Total Non-Current Liabilities fell 65.03% year-over-year to $64196.0; the trailing twelve-month figure through Dec 2022 stood at $64196.0 (down 65.03% YoY), and the FY2022 full-year result was $64196.0, down 65.03% from the prior year.
- Total Non-Current Liabilities declined to $64196.0 in Q4 2022, from $95347.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $1.6 million in Q4 2018 to a low of $31080.0 in Q1 2021.
- A 5-year average of $296837.4 and a median of $169306.5 in 2021 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities plunged 96.11% in 2019 and jumped 398.79% in 2022, its largest moves.
- Tracing TENX's Total Non-Current Liabilities over 5 years: stood at $1.6 million in 2018, then sank by 96.11% to $60379.0 in 2019, then jumped by 105.64% to $124166.0 in 2020, then jumped by 47.86% to $183589.0 in 2021, then sank by 65.03% to $64196.0 in 2022.
- Business Quant data shows TENX's Total Non-Current Liabilities at $64196.0 in Q4 2022, $95347.0 in Q3 2022, and $125883.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Tenax Therapeutics | 67,856.40 | 67,856.40 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 64,196.00 |
| Sep 30, 2022 | 95,347.00 |
| Jun 30, 2022 | 125,883.00 |
| Mar 31, 2022 | 155,024.00 |
| Dec 31, 2021 | 183,589.00 |
| Sep 30, 2021 | 211,590.00 |
| Jun 30, 2021 | 239,039.00 |
| Mar 31, 2021 | 31,080.00 |
| Dec 31, 2020 | 124,166.00 |
| Sep 30, 2020 | 213,757.00 |
| Jun 30, 2020 | 137,051.00 |
| Dec 31, 2019 | 60,379.00 |
| Dec 31, 2018 | 1.55 Mn |
| Sep 30, 2018 | 496,782.00 |
| Jun 30, 2018 | 768,240.00 |
| Mar 31, 2018 | 290,339.00 |
| Dec 31, 2017 | 975,167.00 |
| Sep 30, 2017 | 802,474.00 |
| Jun 30, 2017 | 2.11 Mn |
| Mar 31, 2017 | 4.99 Mn |